Advice
Following an abbreviated submission
New formulation for infants
Creon microgranule formulation is accepted for restricted use in NHS Scotland for the treatment of pancreatic exocrine insufficiency. It provides a formulation suitable for use in young infants and is expected to be used for young cystic fibrosis sufferers who are unable to swallow capsules. The associated resource implications are expected to be small.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- Creon micro (Creon®)
- SMC ID:
- 141/04
- Indication:
- Pancreatic exocrine insufficiency
- Pharmaceutical company
- Solvay Healthcare Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 December 2004